Ignite Creation Date:
2025-12-25 @ 2:26 AM
Ignite Modification Date:
2025-12-30 @ 10:01 PM
Study NCT ID:
NCT02509234
Status:
UNKNOWN
Last Update Posted:
2015-07-27
First Post:
2015-07-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trabectedin and Irinotecan for Refractory Pediatric Sarcomas
Sponsor:
Technical University of Munich
Organization:
Study Overview
Official Title:
Trabectedin and Irinotecan in Pediatric Refractory Sarcomas
Status:
UNKNOWN
Status Verified Date:
2015-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TrIPReSarc
Brief Summary:
The purpose of the study is to evaluate patients with refractory childhood sarcomas, who have been treated with a combination therapy of trabectedin and irinotecan (within compassionate use), to determine, if this is a promising treatment option with acceptable toxicity and if the results warrant a prospective study.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: